



Final Appraisal Recommendation

Advice No: 1618 – October 2018

Semaglutide (Ozempic®) 1.34 mg/ml solution for injection in pre-filled pen

Submission by Novo Nordisk Ltd.

Recommendation of AWMSG

Semaglutide (Ozempic®) is recommended as an option for restricted use within NHS Wales for the treatment of insufficiently controlled type 2 diabetes mellitus in adults as an add-on therapy to oral antidiabetic medicines or basal insulin.

Semaglutide (Ozempic®) is not recommended for use within NHS Wales as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1842), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1618
Semaglutide (Ozempic®) 1.34 mg/ml solution for injection in pre-filled pen October 2018